Pharma Stocks
-
Eisai (TSE:4523) Following Leqembi Home Dosing Approval Is The Alzheimer’s Upside Already Priced In
Eisai (TSE:4523) is back in focus after fresh Alzheimer’s data and a new at-home dosing option for Leqembi. These developments…
Read More » -
Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story?
Alnylam Pharmaceuticals recently presented at the Alzheimer’s Association International Conference 2026 in London, sharing Phase 1 and Phase 2 updates…
Read More » -
Vertex Pharma stock steadies as cystic fibrosis franchise drives revenue and investors watch next da
Vertex Pharmaceuticals Inc. (ISIN US92532F1003) is best known for its cystic fibrosis therapies, and Vertex Pharma stock trades on Nasdaq…
Read More » -
ANI Pharmaceuticals (ANIP) Stock Looks Fairly Valued With Strong Returns But Mixed Earnings
ANI Pharmaceuticals has delivered a strong 139.1% return over the past 5 years, yet at around US$79.20 the valuation checks…
Read More » -
UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow
UroGen Pharma (URGN) is back in focus after the FDA cleared its Investigational New Drug application for UGN-501, allowing the…
Read More » -
Takeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervalued
Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib in…
Read More » -
Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins
Eton Pharmaceuticals has turned heads with a very large 3 year return and a fresh 52 week run, yet its…
Read More » -
Does Shionogi’s Pediatric Fetroja sNDA Shift the Bull Case For Shionogi (TSE:4507)?
Shionogi recently announced that the U.S. FDA has accepted a Supplemental New Drug Application for Fetroja (cefiderocol) to treat pediatric…
Read More » -
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals in an all-stock transaction. Concurrent with the closing, Jasper raised approximately $132…
Read More » -
Does Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?
In July 2026, Takeda reported positive Phase 3 results for its oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque…
Read More »